



## Amicus Therapeutics to Present at J.P. Morgan Healthcare Conference

### - Company will provide update on Phase 3 program for Amigal(TM) -

CRANBURY, N.J., Dec 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --

Amicus Therapeutics (Nasdaq: FOLD) today announced that its President & CEO John F. Crowley will present a corporate overview and the Company's 2009 key business objectives at the 27th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2009, at 11:30 a.m. PT (2:30 p.m. ET). The conference will be held in San Francisco, California.

Mr. Crowley's presentation will include an update regarding the Company's discussions with US and EU regulatory authorities about Phase 3 development of Amigal(TM) (migalastat hydrochloride), an oral therapeutic drug candidate for the treatment of Fabry disease. The Company expects to initiate Phase 3 development of Amigal(TM) in the first half of 2009.

A webcast and audio archive of the presentation will be available at <http://www.amicustherapeutics.com>. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days until February 11, 2009.

#### About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

#### Forward-Looking Statements

This Press release contains certain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such statements include (i) statements regarding the goals, progress and expected timing of clinical studies, including the progress, timing and design of Phase 3 clinical development for Amigal, and (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal. These forward-looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward-looking statements. Important factors that may cause actual results to differ materially from those indicated by forward-looking statements include, among others:

- the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective,
- our dependence on third parties in the conduct of our clinical studies,
- a change in strategy by our collaboration partners, and
- delays or failure to achieve final agreement with regulatory authorities on the design of Phase 3 program for Amigal and the regulatory pathway for approval of Amigal.

These and other risks are described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements because of these uncertainties, and the inclusion of forward-looking statements should not be

regarded as a representation by Amicus that any of its plans will be achieved. We assume no obligation to update forward-looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD-G

SOURCE Amicus Therapeutics

<http://www.amicustherapeutics.com>

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX